Single-Dose Brachytherapy Effective for Prostate Cancer

MONDAY, April 29, 2019 -- Single-dose high dose-rate (HDR) brachytherapy is safe and effective for low-risk prostate cancer, according to a study presented at ESTRO 38, the annual meeting of the European Society for Radiotherapy and Oncology, held...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: May 2019Source: European Urology Supplements, Volume 18, Issue 3Author(s): K. Jokubonis, D. Milonas, Z. Venclovas, K. Vaiciunas
Source: European Urology Supplements - Category: Urology & Nephrology Source Type: research
Publication date: Available online 4 June 2019Source: European UrologyAuthor(s): Sebastian Berg, Alexander Cole, Quoc-Dien Trinh
Source: European Urology - Category: Urology & Nephrology Source Type: research
To evaluate the biochemical freedom from failure (bFFF) by risk group and treatment modality and the predictive factors of bFFF by risk group in patients with prostate cancer undergoing permanent seed implantation (PI) with or without external beam radiation therapy (EBRT) in a nationwide prospective cohort study (Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 [I-125] Seed Implantation) in Japan during the first 2  years.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research
Conclusions: There is an almost equal split among North American GU expert radiation oncologists regarding the appropriateness to consider moderately hypofractionated EBRT as a new standard of care in management of patients with prostate cancer. Physicians who embrace brachytherapy may be more inclined to support moderate hypofractionated regimen for EBRT. It is unclear whether reports with longer follow-ups will impact this balance, or whether national care and reimbursement policies will drive the clinical decisions. In the day and age of patient - centered care delivery, patients should receive an objective recommendati...
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Conclusions: BT was effective as a definitive treatment modality for prostate cancer, and its endpoints and toxicities were comparable to those of the main series in the literature.
Source: International Braz J Urol - Category: Urology & Nephrology Source Type: research
Publication date: Available online 23 May 2019Source: European UrologyAuthor(s): Michael Froehner, Christian Thomas
Source: European Urology - Category: Urology & Nephrology Source Type: research
ConclusionWe generated a second-generation CAR targeting either Lewis Y or GRP-78 with a truncated CD34-tag for purification. Because the differentiation and phenotype of the CAR-T product may have a critical impact on the post-infusion antitumor effect and persistence of the cells, we also investigated the phenotype of CAR-T product with different γc cytokines, i.e. IL-2, IL-7 and IL-15, to generate early differentiation stage cells with less exhaustion phenotypes. In the optimized protocol, by using the retroviral transduction system, starting from 3 × 107 PBMC, we're now able to produce approximately 109...
Source: Cytotherapy - Category: Cytology Source Type: research
We report on the efficacy and adverse effects of the currently available local salvage modalities including salvage radical prostatectomy, high dose rate and low dose rate brachytherapy, cryotherapy, high intensity focused ultrasound, and stereotactic body RT. We additionally discuss diagnosis of oligometastatic disease on imaging and current approaches to treatment with either radiation or surgery. While a full review of chemotherapy and advanced androgen therapies is beyond the scope of this article we briefly discuss their use in the treatment of newly diagnosed recurrence after radiation. PMID: 31133370 [PubMed - ...
Source: Urologic Oncology - Category: Urology & Nephrology Authors: Tags: Urol Oncol Source Type: research
592Objectives: 18F-rhPSMA-7 is a new theranostic PSMA-targeting agent which allows fast radiolabeling with 18F and radiometals. This retrospective analysis investigates the efficacy of 18F-rhPSMA-7 PET/computed tomography (CT) in patients with biochemical recurrence of prostate cancer following curative-intent primary treatment with external beam radiotherapy (EBRT) or brachytherapy. Methods: Datasets from patients with non-castrate biochemical recurrence of prostate cancer after treatment with EBRT or brachytherapy who underwent 18F-rhPSMA-7 PET/CT at either the Technical University Munich or Ludwig-Maximillian University...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Diagnosis I Source Type: research
Conclusions: In biochemical relapse, patients with a negative Choline PET/CT should undergo PSMA-PET/CT given its high expected detection rate. Noteworthy, in cases with PSA higher than 0.5 ng/ml PSMA-PET/CT gives the possibility to lead towards targeted therapies, while efforts should still be done to increase the detection rate in patients with PSA lower than 0.5 ng/ml.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate/GU Imaging Posters Source Type: research
More News: Brachytherapy | Cancer | Cancer & Oncology | Pharmaceuticals | Prostate Cancer | Study